CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
stocks
What did Morningstar subscribers buy and sell during May?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.60 | 54.00 | -0.60% |
| CAC 40 | 8,435.09 | 49.60 | 0.59% |
| DAX 40 | 24,912.73 | 172.37 | 0.70% |
| Dow JONES (US) | 51,848.90 | 182.06 | 0.35% |
| FTSE 100 | 10,527.64 | 66.01 | 0.63% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,476.64 | 110.40 | -0.43% |
| Nikkei 225 | 72,366.34 | 3,191.38 | 4.61% |
| NZX 50 Index | 13,493.05 | 92.39 | 0.69% |
| S&P 500 | 7,358.22 | 7.24 | -0.10% |
| S&P/ASX 200 | 8,748.70 | 51.90 | -0.59% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |